By querying the TCGA (The Cancer Genome Atlas Program) pan-cancer atlas studies, it was found that GRIN2A is altered in 5% of all cancers, with melanoma, lung, colorectal, bladder, and breast cancer having the greatest prevalence of alterations (Figure 6). Here, GRIN2A is linked to melanoma.